Copeland Capital Management LLC Has $30.85 Million Holdings in iRadimed Corporation $IRMD

Copeland Capital Management LLC lowered its position in shares of iRadimed Corporation (NASDAQ:IRMD) by 5.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 433,500 shares of the medical equipment provider’s stock after selling 24,419 shares during the period. Copeland Capital Management LLC owned 3.41% of iRadimed worth $30,848,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. CWM LLC grew its holdings in iRadimed by 62.2% in the 3rd quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 211 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of iRadimed by 191.1% in the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after acquiring an additional 495 shares during the period. Spire Wealth Management acquired a new position in shares of iRadimed in the second quarter valued at about $60,000. Comerica Bank grew its stake in shares of iRadimed by 21.4% in the first quarter. Comerica Bank now owns 2,288 shares of the medical equipment provider’s stock valued at $120,000 after acquiring an additional 404 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey increased its position in iRadimed by 30.2% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 2,056 shares of the medical equipment provider’s stock worth $123,000 after acquiring an additional 477 shares during the period. 92.34% of the stock is owned by institutional investors and hedge funds.

iRadimed Price Performance

NASDAQ IRMD opened at $97.74 on Tuesday. The business has a fifty day moving average price of $89.18 and a two-hundred day moving average price of $74.61. The stock has a market capitalization of $1.24 billion, a PE ratio of 59.24 and a beta of 1.06. iRadimed Corporation has a fifty-two week low of $47.48 and a fifty-two week high of $98.53.

iRadimed (NASDAQ:IRMD) last issued its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $0.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.04. iRadimed had a return on equity of 22.93% and a net margin of 26.31%.The company had revenue of $21.20 million for the quarter, compared to analyst estimates of $20.50 million. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. As a group, sell-side analysts expect that iRadimed Corporation will post 1.66 earnings per share for the current year.

iRadimed Announces Dividend

The business also recently announced a special dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Wednesday, December 17th will be issued a $0.50 dividend. The ex-dividend date of this dividend is Wednesday, December 17th. iRadimed’s dividend payout ratio is 41.21%.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on IRMD shares. Roth Capital set a $90.00 target price on shares of iRadimed in a research report on Friday, October 31st. Wall Street Zen cut iRadimed from a “strong-buy” rating to a “buy” rating in a research note on Sunday, October 26th. Weiss Ratings reissued a “buy (b-)” rating on shares of iRadimed in a research report on Monday, December 22nd. Lake Street Capital reaffirmed a “buy” rating and issued a $100.00 price objective on shares of iRadimed in a report on Monday, November 3rd. Finally, Zacks Research upgraded iRadimed to a “hold” rating in a research report on Tuesday, November 4th. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $87.33.

Insider Buying and Selling

In related news, CEO Roger E. Susi sold 5,000 shares of iRadimed stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $96.73, for a total transaction of $483,650.00. Following the sale, the chief executive officer directly owned 2,287,500 shares of the company’s stock, valued at approximately $221,269,875. The trade was a 0.22% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO John Glenn sold 15,000 shares of the stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $97.29, for a total transaction of $1,459,350.00. Following the completion of the transaction, the chief financial officer directly owned 7,362 shares of the company’s stock, valued at approximately $716,248.98. The trade was a 67.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 65,000 shares of company stock worth $5,548,150. 36.80% of the stock is currently owned by corporate insiders.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.